Foundayo Weight Loss Pill in Australia Gets Regulatory Approval & Soon To Hit Pharmacies

Foundayo weight loss pill in Australia

Follow Us:

November 17, 2026

Overview :

US pharmaceutical company Eli Lilly’s weight loss pill Foundayo has received approval from Australia’s Therapeutic Goods Administration (TGA), giving patients another oral option for managing obesity and type 2 diabetes.

After the recent TGA approval for Novo’s Wegovy, the Foundayo weight loss pill in Australia will expand the country’s oral GLP-1 treatment market. The company expects Foundayo to reach Australian pharmacies within days.

Lilly’s Foundayo is already approved by regulators in the USA and the UK for patients.

About Eli Lilly’s Weight Loss Pill Foundayo

The TGA approval for Foundayo pill took place on November 16, 2026, under the Australian Register of Therapeutic Goods. Marketed by Eli Lilly, Foundayo is a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. It is a once-daily medication that contains orforglipron, an active ingredient that helps regulate appetite and blood sugar levels.

Unlike traditional injectable GLP-1 treatments, Foundayo comes as a daily tablet. It is approved for chronic weight management in eligible adults and for treating type 2 diabetes alongside a healthy diet and physical activity.

According to Eli Lilly Australia General Manager Dr Manny Simons, the medicine’s clinical trials involved more than 10,000 participants across 15 countries, including partnerships with 12 Australian hospitals and clinics.

Foundayo Drug Availability in Australia and Monthly Price

Eli Lilly expects Foundayo weight loss pill in Australia to arrive within days of regulatory approval. Patients will need a prescription from a healthcare professional to access the medicine through community pharmacies.

The Foundayo’s price in Australia is expected to range between AUD $250 and $370 per month, depending on the dosage. However, the medicine is not currently listed on the Pharmaceutical Benefits Scheme (PBS) for weight management. This means most patients seeking it for obesity treatment will need to pay privately.

The cost could limit access for some Australians despite the availability of another oral treatment option.

Differences Between Foundayo and Wegovy Pill

The regulatory approval of Foundayo weight loss pill in Australia follows Novo Nordisk’s recent TGA approval for its oral Wegovy tablet. Both medicines belong to the GLP-1 drug class, but their active ingredients and administration requirements differ.

  • Foundayo: Contains orforglipron and can be taken once daily at any time, without food or water restrictions.
  • Wegovy tablet: Contains semaglutide and requires patients to take it first thing in the morning on an empty stomach.

Foundayo costs approximately AUD 250–370, while oral Wegovy has a recommended monthly price of AUD 260–395, depending on the dose.

Novo Nordisk expects its tablet to become available by the end of 2026, while Lilly anticipates an earlier pharmacy rollout.

The Eligibility Criteria For Foundayo Pill

The Foundayo weight loss pill in Australia is approved for adults who meet specific medical criteria:

  • People with a body mass index (BMI) of 30 or higher.
  • People with a BMI of 27 or higher who also have a weight-related condition, such as hypertension, prediabetes, cardiovascular disease or sleep apnoea.
  • Adults with type 2 diabetes, alongside dietary changes and physical activity.

However, the medication is not suitable for everyone. Common side effects of oral Foundayo include nausea and other digestive problems, which may become more noticeable when doctors increase the dosage.

Lilly also warns about low blood sugar when patients combine Foundayo with insulin or sulfonylureas, as well as the risk of pancreatitis. Foundayo should not be used during pregnancy, and certain drug interactions require medical attention.

Healthcare professionals should assess patients before prescribing Foundayo for treatment and monitor them throughout its use.

Sanskruti Jadhav is an SEO content writer at Global Healthcare Magazine. She specializes in creating healthcare and business content through blogs, news articles, and digital content for diverse audiences. A graduate in Journalism and Mass Communication, she aims to deliver authentic and impactful information through her writing.